IceCure Medical (NASDAQ:ICCM – Get Free Report) and Embecta (NASDAQ:EMBC – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Risk and Volatility
IceCure Medical has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Embecta has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
Earnings & Valuation
This table compares IceCure Medical and Embecta”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IceCure Medical | $3.95 million | 0.84 | -$29.19 million | ($8.52) | -0.11 |
| Embecta | $1.02 billion | 0.36 | $83.86 million | $1.48 | 4.37 |
Embecta has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 1.3% of Embecta shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares IceCure Medical and Embecta’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IceCure Medical | N/A | N/A | N/A |
| Embecta | N/A | N/A | N/A |
Analyst Ratings
This is a summary of current recommendations for IceCure Medical and Embecta, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IceCure Medical | 1 | 1 | 2 | 0 | 2.25 |
| Embecta | 2 | 3 | 0 | 0 | 1.60 |
IceCure Medical currently has a consensus target price of $30.00, indicating a potential upside of 2,989.60%. Embecta has a consensus target price of $11.00, indicating a potential upside of 70.15%. Given IceCure Medical’s stronger consensus rating and higher possible upside, equities analysts clearly believe IceCure Medical is more favorable than Embecta.
Summary
Embecta beats IceCure Medical on 6 of the 11 factors compared between the two stocks.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
About Embecta
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
